Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2025-12-26 @ 2:35 AM
Study NCT ID:
NCT07213960
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-10-09
First Post:
2025-09-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Sponsor:
Apellis Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12
Start Date Type:
ESTIMATED
Primary Completion Date:
2029-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-15
First Submit QC Date:
None
Study First Post Date:
2025-10-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-02
Last Update Post Date:
2025-10-09
Last Update Post Date Type:
ESTIMATED